About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
Recent Quotes
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

By: ACCESSWIRE

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE: BHC)(TSX:BHC), today announced that its topical prescription treatment for acne vulgaris, PrARAZLOTM (tazarotene lotion, 0.045% w/w), is now available to patients through BC PharmaCare, the public drug program of British Columbia.

ARAZLO is the only tazarotene lotion treatment approved by Health Canada for the topical treatment of acne vulgaris in patients 10 years of age and older.1 The listing by BC PharmaCare means ARAZLO is now available to patients on all public drug plans across Canada.

"We are very pleased that British Columbia residents who rely on BC PharmaCare now have access to ARAZLO, a retinoid lotion with a unique vehicle technology for the treatment of acne vulgaris," Cees Heiman, Senior Vice-President, Europe and Canada, Bausch Health said. "It is an important part of our large dermatology portfolio to help meet Canadians' skin care needs."

ARAZLO is the only tazarotene acne treatment available in a lotion formulated with PRISMATREXTM technology (formulation with known hydrating and moisturizing effects, which may alleviate dryness of skin).1 Retinoids like tazarotene are a core component of acne treatment. Providing the treatment in a lotion form helps limit the dryness and irritation that has historically been a barrier to the long-term use of tazarotene by patients.2

"The technology in ARAZLO lotion can help with patient tolerability of their acne treatment which can lead to better effectiveness and results for the patient, so it is very positive that ARAZLO is now available to patients through BC PharmaCare," said Dr. Christina Han, a dermatologist practicing in Vancouver and Clinical Assistant Professor with the Department of Dermatology and Skin Science at the University of British Columbia. "In treating acne, it's important to have a variety of treatment options to find the right one for each patient."

Approximately 5.6 million Canadians are impacted by acne3 and often need to try different treatment options to find one that is effective for them.

"It's encouraging and useful for people with acne to have new treatment options available to them through our public drug plans as acne can have a negative impact on their lives," said Sue Sherlock, Executive Director of the Acne and Rosacea Society of Canada. "It is good news when a new treatment becomes accessible to everyone."

ARAZLO is produced by Bausch Health, Canada for Canadian patients and for export at the company's manufacturing facility in Laval, Quebec.

About Acne Vulgaris
Acne vulgaris ("vulgaris" means "common") is the most common skin problem seen by doctors in Canada. It occurs when the pores of the skin become plugged with oil and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Acne affects about 5.6 million Canadians, or nearly 20 per cent of the population and causes emotional distress and can cause permanent scarring1 or pigmentation changes.4 Acne affects about 90 per cent of adolescents and about 25 per cent of teens will still have acne at age 25.3

About ARAZLO
ARAZLO tazarotene lotion, 0.045% w/w is a topical prescription indicated for the topical treatment of acne vulgaris. ARAZLO can be used on affected areas in patients 12 years and older and on affected areas of the face only of those aged 10 and 11. The safety and efficacy of ARAZLO in children below the age of 10 years has not been established.1

About Bausch Health

Bausch Health Companies Inc. (NYSE: BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, healthcare professionals, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

The Bausch Health Canadian prescription treatment portfolio is focused on dermatology, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada: in Laval, Quebec, and Steinbach, Manitoba. More information can be found at the Company's website at www.bauschhealth.ca.

REFERENCES

1. PrARAZLO® (Tazarotene Lotion, 0.045% w/w) Product Monograph, July 7, 2021.

2. "Targeted Topical Delivery of Retinoids in the Management of Acne Vulgaris: Current Formulations and Novel Delivery Systems." Pharmaceutics. Gemma Latter et al, October 2019, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835300/, accessed Nov. 1, 2022.

3. Canadian Dermatology Association, Acne, Quick Facts, https://dermatology.ca/public-patients/skin/acne/#:~:text=Acne%20affects%205.6%20million%20Canadians,adults%20ages%2020%20to%2040, accessed Nov. 1, 2022.

4. "What to Know about Hyperpigmentation Acne." Medical News Today, Jessica Caporuscio, April 28, 2021, https://www.medicalnewstoday.com/articles/hyperpigmentation-acne, accessed Nov. 1, 2022.

Investor Contact:

ir@bauschhealth.com
(877) 281-6642 (toll free)

Media Contact:

Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785

SOURCE: Bausch Health Companies Inc.



View the original press release on accesswire.com

More News

View More
Where 3M’s Q3 Report Says the Stock Price Is Heading
Via MarketBeat
Tickers MMM
META's Next Big Test: Previewing Its Fast-Approaching Q3 Earnings
Via MarketBeat
Tickers GOOGL META MSFT
Beware The Death Cross: 3 Stocks Triggering This Spooky Signal
Via MarketBeat
Topics ETFs
Tickers ASX:TWR BSX DRI SYK
2 Ways to Trade Qualcomm Ahead of November’s Earnings
Via MarketBeat
Topics Artificial Intelligence
Tickers NVDA QCOM
Lululemon: 2 Signs the Bottom Is In, and 1 Sign It Isn’t
Via MarketBeat
Tickers LULU NKE

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.92
-3.11 (-1.40%)
AAPL  260.31
-2.46 (-0.94%)
AMD  238.55
+0.52 (0.22%)
BAC  51.29
-0.23 (-0.45%)
GOOG  255.85
+4.51 (1.79%)
META  737.74
+4.47 (0.61%)
MSFT  522.68
+5.02 (0.97%)
NVDA  183.17
+2.01 (1.11%)
ORCL  276.03
+0.88 (0.32%)
TSLA  441.75
-0.85 (-0.19%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.